1e
19
1
49
2
2
18
1b
1d
18
37
45
1d
2 29
1d
25
J. Deanna Wilson, MD, MPH
88
45
Presidential Assistant Professor
7
7b
Department: Family Medicine and Community Health
4
1
b
1d
46
Contact information
4e
4
3
3
3
2
4
b
1f
4e
Penn Presbyterian Medical Center
1d Andrew Mutch Building
34 51 N. 39th Street
Philadelphia, PA 19104
26
1d Andrew Mutch Building
34 51 N. 39th Street
Philadelphia, PA 19104
35
b3
12
13
Education:
21 7 BA 25 (Sociology & Anthropology) c
2b Swarthmore College, 2004.
21 7 MD 15 (Medicine) c
3b Yale University School of Medicine, 2010.
21 8 MPH 2b (Social and Behavioral Sciences) c
49 Johns Hopkins Bloombergy School of Public Health, 2015.
c
3
3
3
3
8d
Permanent link21 7 BA 25 (Sociology & Anthropology) c
2b Swarthmore College, 2004.
21 7 MD 15 (Medicine) c
3b Yale University School of Medicine, 2010.
21 8 MPH 2b (Social and Behavioral Sciences) c
49 Johns Hopkins Bloombergy School of Public Health, 2015.
c
2 29
21
1e
1d
24
5e
71
e 29
27
Description of Clinical Expertise
da Addiction medicine across the life-spectrum (including substance use and substance use disorder treatment in adolescents and young adults), addiction medicine in office-based and hospital-based settings71
Description of Research Expertise
270 My current research leverages traditional health services research methods, community-engaged research methods, and implementation science to build health equity for marginalized and racially minoritized populations who use drugs. My work focuses on examining how best to integrate harm reduction into primary care and hospital-based settings, hot to develop low threshold models of care to improve engagement and retention of often marginalized and racially and ethnically minoritized populations, and how to improve engagement and retention of adolescents and young adults in opioid use disorder treatment.e 29
23
10d Leon K, Weger R, Weinstock N, Jawa R, Wilson JD.: "It's nothing personal": understanding barriers to relational harm reduction practices during inpatient hospitalization. Harm Reduct J. Jun 2025.
1bc Salay M, Edwards KA, Winstanley EL, Bachrach RL, Bulls HW, Hanmer J, Liebschutz JM, Robbins J, Wilson JD, Yu L, Merlin JS, Murray-Krezan C.: Study Protocol for Pain Self-Management and Patient-Oriented Buprenorphine Dosing for Pain and Retention in Office-Based Opioid Treatment: A Hybrid Type 1, 2 × 2 Factorial Randomized Controlled Trial. Subst Use Addctn J Jan 2025.
128 Hamm M, Wilson JD, Lee YJ, Norman N, Winstanley EL, McTigue KM. : Substance use as subtext to health narratives: Identifying opportunities for improving carefrom community member perspectives. Patient Educ Couns. Nov 2024.
82 Weger R, Weinstock N, Jawa R, Wilson JD. : "We're Not Gonna Aid You in Shooting 54 Up": Stigma's Relationship to Harm Reduction in People Who Inject Drugs. J Gen 29 Intern Med. Oct 2024.
117 O'Brien C, Klipp S, Jawa R, Wilson JD: Community pharmacists' attitudes toward and practice of pharmacy-based harm reduction services in Pittsburgh, PA: a descriptive survey. Harm Reduct J 21(1), Jul 2024.
f5 Rider-Longmaid E, Wilson JD. : Ushering in a New Paradigm of Substance Use Prevention-Low-Touch Personalized Interventions in Specialty Care. JAMA Netw Open 7(7), Jul 2024.
169 Lim G, Xue L, Donohue JM, Junker S, Wilson JD, Suffoletto B, Lynch MJ, Pacella-LaBarbara ML, Chang CH, Krans E, Jarlenski M. : Associations between acute pain after vaginal delivery and postpartum opioid prescription fills: a retrospective case-controlled study. Br J Anaesth. May 2024.
17b Herrera MC, Johnson J, Lim S, Morales KH, Wilson JD, Hadland SE, Metzger D, Wood S, Dowshen N. : Co-delivery of HIV pre-exposure prophylaxis (PrEP) and HIV testing among publicly insured adolescents and young adults (AYA) receiving medication for opioid use disorder (MOUD). Drug Alcohol Depend. Apr 2024.
136 Green E, Hamm M, Gowl C, Van Deusen R, Liebschutz JM, Wilson JD, Merlin J.: Optimizing evidence-based practice implementation: a case study on simulated patient protocols in long-term opioid therapy. Implement Sci Commun. 5(1), Apr 2024.
2c
7
1d
1f
Selected Publications
72 Wilson JD, Klipp SP, Leon K, Liebschutz JM, Merlin J, Murray-Krezan C, 55 Nolette S, Phillips KT, Stein M, Weinstock N, Hamm M.: "To not feel fake, it 50 can't be fake": co-creation of a harm reduction, peer-delivered, health-system 56 intervention for people who use drugs. Harm Reduct J Jun 2025.10d Leon K, Weger R, Weinstock N, Jawa R, Wilson JD.: "It's nothing personal": understanding barriers to relational harm reduction practices during inpatient hospitalization. Harm Reduct J. Jun 2025.
1bc Salay M, Edwards KA, Winstanley EL, Bachrach RL, Bulls HW, Hanmer J, Liebschutz JM, Robbins J, Wilson JD, Yu L, Merlin JS, Murray-Krezan C.: Study Protocol for Pain Self-Management and Patient-Oriented Buprenorphine Dosing for Pain and Retention in Office-Based Opioid Treatment: A Hybrid Type 1, 2 × 2 Factorial Randomized Controlled Trial. Subst Use Addctn J Jan 2025.
128 Hamm M, Wilson JD, Lee YJ, Norman N, Winstanley EL, McTigue KM. : Substance use as subtext to health narratives: Identifying opportunities for improving carefrom community member perspectives. Patient Educ Couns. Nov 2024.
82 Weger R, Weinstock N, Jawa R, Wilson JD. : "We're Not Gonna Aid You in Shooting 54 Up": Stigma's Relationship to Harm Reduction in People Who Inject Drugs. J Gen 29 Intern Med. Oct 2024.
117 O'Brien C, Klipp S, Jawa R, Wilson JD: Community pharmacists' attitudes toward and practice of pharmacy-based harm reduction services in Pittsburgh, PA: a descriptive survey. Harm Reduct J 21(1), Jul 2024.
f5 Rider-Longmaid E, Wilson JD. : Ushering in a New Paradigm of Substance Use Prevention-Low-Touch Personalized Interventions in Specialty Care. JAMA Netw Open 7(7), Jul 2024.
169 Lim G, Xue L, Donohue JM, Junker S, Wilson JD, Suffoletto B, Lynch MJ, Pacella-LaBarbara ML, Chang CH, Krans E, Jarlenski M. : Associations between acute pain after vaginal delivery and postpartum opioid prescription fills: a retrospective case-controlled study. Br J Anaesth. May 2024.
17b Herrera MC, Johnson J, Lim S, Morales KH, Wilson JD, Hadland SE, Metzger D, Wood S, Dowshen N. : Co-delivery of HIV pre-exposure prophylaxis (PrEP) and HIV testing among publicly insured adolescents and young adults (AYA) receiving medication for opioid use disorder (MOUD). Drug Alcohol Depend. Apr 2024.
136 Green E, Hamm M, Gowl C, Van Deusen R, Liebschutz JM, Wilson JD, Merlin J.: Optimizing evidence-based practice implementation: a case study on simulated patient protocols in long-term opioid therapy. Implement Sci Commun. 5(1), Apr 2024.
2c